(Reuters) -Halozyme Therapeutics Inc is bolstering its drug delivery platform with a $960 million all-cash deal for specialty pharmaceutical company Antares Pharma Inc, the companies said on Wednesday ...
Halozyme Therapeutics Inc., headquartered in San Diego, and Antares Pharma Inc. of Ewing Township announced April 13 that they entered into a definitive agreement for Halozyme to acquire Antares for ...
Having struck partnerships with the likes of Johnson & Johnson, GlaxoSmithKline and Roche, Halozyme is best known for its under-the-skin drug delivery platform. Now, the company is buying into the ...
Halozyme Therapeutics HALO announced that it has entered into a definitive agreement with Antares Pharma ATRS to acquire the latter for approximately $960 million. The acquisition will add Antares’ ...
Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business ...
With over 30 years of experience in drug device engineering, Antares Pharma has nurtured its R&D prowess and specialized in creating custom designed drug delivery devices that are tailored to the ...
EWING, N.J., May 16, 2017 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) announced that data from its Phase 3 study of the pharmacokinetics and safety of subcutaneous testosterone enanthate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback